Treatment with BIIB122/DNL151 achieved robust reductions in biomarkers of target engagement and pathway engagement in healthy volunteers and patients with Parkinson’s disease
BIIB122/DNL151 demonstrated a safety profile supporting continued development in patients with Parkinson’s disease
Data support once daily oral dosing with BIIB122/DNL151
Denali and Biogen plan to advance BIIB122/DNL151 into late-stage development in patients with Parkinson’s disease by year-end 2021
This is a report on their LRRK-2 (gene mutation) drug BIIB122/DNL151 using biomarkers to assess results on primarily healthy volunteers without PD..
Positive results were seen in "biomarkers"( ...a measurable substance (sP935) in a blood sample whose presence is indicative of some disease such as PD mutated LRRK-2,) "the magnitude of reduction required for normalization of increased LRRK2 kinase activity observed in Parkinson’s patients with kinase activating LRRK2 mutations."
Will these results translate to PD patients who are actually LRRK-2? Long way to go.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.